TY - JOUR T1 - Serum proteomic profiling of rheumatoid arthritis–interstitial lung disease with a comparison to idiopathic pulmonary fibrosis JF - Thorax JO - Thorax SP - 1041 LP - 1044 DO - 10.1136/thorax-2021-217822 VL - 77 IS - 10 AU - Xiaoping Wu AU - Yunju Jeong AU - Sergio Poli de Frías AU - Imaani Easthausen AU - Katherine Hoffman AU - Clara Oromendia AU - Shahrad Taheri AU - Anthony J Esposito AU - Luisa Quesada Arias AU - Ehab A Ayaub AU - Rie Maurer AU - Ritu R Gill AU - Hiroto Hatabu AU - Mizuki Nishino AU - Michelle L Frits AU - Christine K Iannaccone AU - Michael E Weinblatt AU - Nancy A Shadick AU - Paul F Dellaripa AU - Augustine M K Choi AU - Edy Y Kim AU - Ivan O Rosas AU - Fernando J Martinez AU - Tracy J Doyle Y1 - 2022/10/01 UR - http://thorax.bmj.com/content/77/10/1041.abstract N2 - Although interstitial lung disease (ILD) causes significant morbidity and mortality in rheumatoid arthritis (RA), it is difficult to predict the development or progression of ILD, emphasising the need for improved discovery through minimally invasive diagnostic tests. Aptamer-based proteomic profiling was used to assess 1321 proteins from 159 patients with rheumatoid arthritis with interstitial lung disease (RA-ILD), RA without ILD, idiopathic pulmonary fibrosis and healthy controls. Differential expression and gene set enrichment analyses revealed molecular signatures that are strongly associated with the presence and severity of RA-ILD and provided insight into unexplored pathways of disease. These warrant further study as non-invasive diagnostic tools and future therapeutic targets. ER -